Int J Cardiol:利拉鲁肽对非糖尿病超重女性冠状动脉微血管功能障碍患者体重和微血管功能的影响

2019-01-03 xing.T MedSci原创

由此可见,利拉鲁肽治疗导致显著的体重减轻和血压降低,治疗期间没有伴随的症状缓解,并且冠状动脉微血管功能也没有改善。

冠状动脉微血管功能障碍(CMD)与血管不良结局相关,CMD是2型糖尿病的标志。利拉鲁肽通过部分未知的机制改善心血管预后。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,研究人员假设在非糖尿病超重的心绞痛和无阻塞性冠状动脉疾病(CAD)患者中,利拉鲁肽治疗可通过体重减轻改善CMD和症状。

研究人员在开放标签概念验证研究中纳入了33名非糖尿病超重女性(BMI>25),这些患者伴有CMD(冠状动脉血流速度储备(CFVR)≤2.5)、心绞痛症状,但无梗阻性CAD。该方案包含了5周的对照期,然后是利拉鲁肽的干预期,每天3mg,持续12周。在对照期之前和之后以及在最后一次利拉鲁肽剂量后1-2周再次对参与者进行研究。主要结果是在干预期间通过西雅图心绞痛问卷(SAQ)测量的CFVR和心绞痛症状变化与对照期进行比较。

二十九名参与者完成了这项研究。利拉鲁肽治疗导致显著的体重减轻(平均为6.03kg(95%CI为5.22-6.84))和收缩压降低(平均为10.95mmHg(95%CI为4.60-17.30))。基线中值CFVR为2.30(IQR 为1.91-2.51),并且在接受利拉鲁肽治疗后保持不变(平均变化为0.07(95%CI为-0.07-0.21))。对SAQ测量的症状或左心室收缩压参数以及舒张功能均无影响。

由此可见,利拉鲁肽治疗导致显著的体重减轻和血压降低,治疗期间没有伴随的症状缓解,并且冠状动脉微血管功能也没有改善。 


链接:西雅图心绞痛量表(SAQ)

原始出处:


Hannah ElenaSuhrs,et al.Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.International Journal of Cardiology.2018.https://doi.org/10.1016/j.ijcard.2018.12.005

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
    2019-01-05 mgqwxj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1991181, encodeId=ddf91991181fa, content=<a href='/topic/show?id=b29c99594dd' target=_blank style='color:#2F92EE;'>#非糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99594, encryptionId=b29c99594dd, topicName=非糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Wed Nov 06 21:45:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781993, encodeId=35891e81993c1, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 22 08:45:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718698, encodeId=8c1d1e1869845, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Fri Jul 12 23:45:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365364, encodeId=83a5136536427, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421206, encodeId=ac39142120633, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511991, encodeId=9a431511991c2, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581711, encodeId=e0a21581e11a5, content=<a href='/topic/show?id=671730856fd' target=_blank style='color:#2F92EE;'>#冠状动脉微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30856, encryptionId=671730856fd, topicName=冠状动脉微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a52716868322, createdName=ms1774076774505970, createdTime=Sat Jan 05 06:45:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042179, encodeId=2f8010421e9fd, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jan 03 18:45:00 CST 2019, time=2019-01-03, status=1, ipAttribution=)]
    2019-01-03 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Lancet Diabetes Endocrinol:糖尿病药物利拉鲁肽或能有效降低患者心血管疾病事件的风险

利拉鲁肽的使用还与患者心血管疾病死亡风险降低以及任何原因导致的死亡风险降低直接相关,在亚群分析中,研究者指出,有心血管疾病史的患者似乎会因利拉鲁肽疗法而获益,尽管其与无疾病史患者之间并无统计学意义。最后研究者Bjorn Pasternak说道,本文研究表明,药物利拉鲁肽在更广泛的未选择的患者群体中能带来心血管健康的益处,同时还能提供重要的临床验证证据。

GLP-1受体激动剂临床应用专家指导意见

目前,我国已上市的GLP-1受体激动剂包括艾塞那肽、利拉鲁肽、贝那鲁肽、利司那肽和艾塞那肽周制剂。为使我国临床医生及时、全面了解该类药物的最新临床证据,并在临床实践中更好的发挥该类药物的作用,我国部分临床专家在系统回顾GLP-1受体激动剂的临床证据和相关指南的基础上达成该类药物临床应用的共识并制定《GLP-1受体激动剂临床应用专家指导意见》,对GLP-1受体激动剂的临床应用及相关证据进行全面介绍。

JAHA:利拉鲁肽治疗改善糖尿病患者内皮细胞内质网应激和胰岛素抵抗

总之,该研究的数据表明ER应激导致DM患者的血管胰岛素抵抗和内皮功能障碍。此外,该研究还在来自DM患者的内皮细胞中证明了利拉鲁肽可改善ER应激,降低c-jun N-末端激酶活化并恢复胰岛素介导的内皮一氧化氮合酶活化。

Diabetes Care:利拉鲁肽对心血管事件高风险的2型糖尿病患者DFU及相关并发症的影响

由此可见,与安慰剂相比,利拉鲁肽治疗CV事件高风险的2型糖尿病患者并未增加DFU事件的风险,并且与DFU相关截肢的风险显著降低。这种关联可能是偶然的,需要进一步调查。

Circulation:利拉鲁肽对2型糖尿病合并慢性肾病患者心血管事件的影响

由此可见,将利拉鲁肽加入到标准治疗中可降低T2D合并CKD患者发生重大心血管事件和全因死亡的风险。

Diabetes Obes Metab:利拉鲁肽对2型糖尿病合并高血压患者动态血压的影响

由此可见,基于24小时动态测量,利拉鲁肽的短期治疗对收缩压会产生有利影响,同时增快心率。